Print Page | Close Page

 
 

Ubiquigent

Address: University Incubator, Dundee Technopole,, James Lindsay Place,, Dundee, Scotland. DD1 5JJ
 
Country: United Kingdom
 
Sectors: Collaborations & Partnerships- R&D, Collaborations & Partnerships-Licensing, Contract Research & Development, Proprietary Research & Manufacture
 
Website: https://www.ubiquigent.com
 
- - -
 

About Us

Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need. Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS). As the partner chosen by many leading industry and academic organisations for their drug discovery programmes, Ubiquigent’s experience spans the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis. Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for partnering and commercialisation.

 
- - -
 

Sectors

  • Collaborations & Partnerships- R&D
  • Collaborations & Partnerships-Licensing
 
  • Contract Research & Development
  • Proprietary Research & Manufacture
 
- - -
 

Categories

  • Biologics
  • Drug Discovery Services
  • Platform Technology-Drug Development
 
  • Platform Technology-Drug Discovery
  • Clinical Development-Pipeline
 
- - -
 

News

 
23rd October 2024
 

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

 

Dundee, UK, and San Francisco, US, 15 October 2024: Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases. The partnership will combine Alleo’s AI-based approach to developing novel therapeutics with Ubiquigent’s platform and expertise in the field of DUB focused drug discovery. Financial details were not disclosed.

 
- - -
 
Printed: 16-Apr-2026 at 09:55:10 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com